Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer.

Cancer treatment and research communications - 1 Jan 2021

Ottestad Anine Larsen, Dai Hong Yan, Halvorsen Tarje Onsøien, Emdal Elisabeth Fritzke, Wahl Sissel Gyrid Freim, Grønberg Bjørn Henning

Abstract excerpt

INTRODUCTION: Studies have indicated that detection of mutated KRAS or EGFR in circulating tumor DNA (ctDNA) from pre-treatment plasma samples is a negative prognostic factor for non-small cell lung cancer (NSCLC) patients. This study aims to investigate whether this is the case also for NSCLC patients with other tumor mutations. METHODS: Tumor tissue DNA from 107 NSCLC patients was sequenced and corresponding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Cell-Free Nucleic Acids

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Share to Survival Analysis

Source

Identifiers

PMID: 34607221
DOI: 10.1016/j.ctarc.2021.100471

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer.PMID 34607221Read ↗

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Semantic proximity Read ↗

Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.Semantic proximity Read ↗

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.Semantic proximity Read ↗

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.Semantic proximity Read ↗

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsSemantic proximity Read ↗

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.Semantic proximity Read ↗

Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.Semantic proximity Read ↗

Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patientsSemantic proximity Read ↗

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.